Cargando…
Association Between Janus Kinase Inhibitors Therapy and Mental Health Outcome in Rheumatoid Arthritis: A Systematic Review and Meta-analysis
INTRODUCTION: Rheumatoid arthritis (RA) is a chronic debilitating illness, usually associated with mental health ailments. Literature reports contradictory observations about the association between recent RA pharmacotherapies and mental health. We systematically reviewed RA randomized control trial...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8964882/ https://www.ncbi.nlm.nih.gov/pubmed/34902113 http://dx.doi.org/10.1007/s40744-021-00409-6 |
_version_ | 1784678310960168960 |
---|---|
author | Shamail, Ghazala M. H. Haridoss, Madhumitha Natarajan, Meenakumari Joshua, Vasna Bagepally, Bhavani Shankara |
author_facet | Shamail, Ghazala M. H. Haridoss, Madhumitha Natarajan, Meenakumari Joshua, Vasna Bagepally, Bhavani Shankara |
author_sort | Shamail, Ghazala M. H. |
collection | PubMed |
description | INTRODUCTION: Rheumatoid arthritis (RA) is a chronic debilitating illness, usually associated with mental health ailments. Literature reports contradictory observations about the association between recent RA pharmacotherapies and mental health. We systematically reviewed RA randomized control trials to synthesize the association between Janus kinases (JAK) inhibitors therapy and mental health. METHODS: We systematically searched clinical trials of JAK inhibitor intervention reporting mental health outcomes using short form-36 (SF-36) in PubMed, Embase, and Scopus databases from inception to February 2021. We have selected the studies and extracted the data, adhering to Preferred Reporting Items of Systematic reviews and Meta-Analysis (PRISMA) guidelines. We have pooled the mean change of SF-36 mental component score (MCS) between JAK inhibitors and comparator therapy with a 95% confidence interval. RESULTS: Of the 2915 searched studies for systematic review, 19 studies involving 14,323 individuals were included for the meta-analysis. The pooled mean reduction in SF-36 MCS scores (after minus before) with JAK inhibitors was 4.95 (4.41–5.48). The pooled mean difference of incremental mean change in SF-36 MCS score between JAK monotherapy and comparator was 1.53 (0.88–2.18). The improvement in SF-36 MCS scores with JAK inhibitor therapy is greater than the minimum clinically important difference (MCID) value of 2.5. However, on separate analysis with comparator drugs like methotrexate and standard treatment, the MCS scores did not exceeded the MCID value and were also not statistically significant. CONCLUSIONS: JAK inhibitors results in clinically meaningful improvement in the mental health scores of the RA patients. PROSPERO REGISTRATION ID: 2021 CRD42021234466. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40744-021-00409-6. |
format | Online Article Text |
id | pubmed-8964882 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-89648822022-04-12 Association Between Janus Kinase Inhibitors Therapy and Mental Health Outcome in Rheumatoid Arthritis: A Systematic Review and Meta-analysis Shamail, Ghazala M. H. Haridoss, Madhumitha Natarajan, Meenakumari Joshua, Vasna Bagepally, Bhavani Shankara Rheumatol Ther Review INTRODUCTION: Rheumatoid arthritis (RA) is a chronic debilitating illness, usually associated with mental health ailments. Literature reports contradictory observations about the association between recent RA pharmacotherapies and mental health. We systematically reviewed RA randomized control trials to synthesize the association between Janus kinases (JAK) inhibitors therapy and mental health. METHODS: We systematically searched clinical trials of JAK inhibitor intervention reporting mental health outcomes using short form-36 (SF-36) in PubMed, Embase, and Scopus databases from inception to February 2021. We have selected the studies and extracted the data, adhering to Preferred Reporting Items of Systematic reviews and Meta-Analysis (PRISMA) guidelines. We have pooled the mean change of SF-36 mental component score (MCS) between JAK inhibitors and comparator therapy with a 95% confidence interval. RESULTS: Of the 2915 searched studies for systematic review, 19 studies involving 14,323 individuals were included for the meta-analysis. The pooled mean reduction in SF-36 MCS scores (after minus before) with JAK inhibitors was 4.95 (4.41–5.48). The pooled mean difference of incremental mean change in SF-36 MCS score between JAK monotherapy and comparator was 1.53 (0.88–2.18). The improvement in SF-36 MCS scores with JAK inhibitor therapy is greater than the minimum clinically important difference (MCID) value of 2.5. However, on separate analysis with comparator drugs like methotrexate and standard treatment, the MCS scores did not exceeded the MCID value and were also not statistically significant. CONCLUSIONS: JAK inhibitors results in clinically meaningful improvement in the mental health scores of the RA patients. PROSPERO REGISTRATION ID: 2021 CRD42021234466. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40744-021-00409-6. Springer Healthcare 2021-12-13 /pmc/articles/PMC8964882/ /pubmed/34902113 http://dx.doi.org/10.1007/s40744-021-00409-6 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Review Shamail, Ghazala M. H. Haridoss, Madhumitha Natarajan, Meenakumari Joshua, Vasna Bagepally, Bhavani Shankara Association Between Janus Kinase Inhibitors Therapy and Mental Health Outcome in Rheumatoid Arthritis: A Systematic Review and Meta-analysis |
title | Association Between Janus Kinase Inhibitors Therapy and Mental Health Outcome in Rheumatoid Arthritis: A Systematic Review and Meta-analysis |
title_full | Association Between Janus Kinase Inhibitors Therapy and Mental Health Outcome in Rheumatoid Arthritis: A Systematic Review and Meta-analysis |
title_fullStr | Association Between Janus Kinase Inhibitors Therapy and Mental Health Outcome in Rheumatoid Arthritis: A Systematic Review and Meta-analysis |
title_full_unstemmed | Association Between Janus Kinase Inhibitors Therapy and Mental Health Outcome in Rheumatoid Arthritis: A Systematic Review and Meta-analysis |
title_short | Association Between Janus Kinase Inhibitors Therapy and Mental Health Outcome in Rheumatoid Arthritis: A Systematic Review and Meta-analysis |
title_sort | association between janus kinase inhibitors therapy and mental health outcome in rheumatoid arthritis: a systematic review and meta-analysis |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8964882/ https://www.ncbi.nlm.nih.gov/pubmed/34902113 http://dx.doi.org/10.1007/s40744-021-00409-6 |
work_keys_str_mv | AT shamailghazalamh associationbetweenjanuskinaseinhibitorstherapyandmentalhealthoutcomeinrheumatoidarthritisasystematicreviewandmetaanalysis AT haridossmadhumitha associationbetweenjanuskinaseinhibitorstherapyandmentalhealthoutcomeinrheumatoidarthritisasystematicreviewandmetaanalysis AT natarajanmeenakumari associationbetweenjanuskinaseinhibitorstherapyandmentalhealthoutcomeinrheumatoidarthritisasystematicreviewandmetaanalysis AT joshuavasna associationbetweenjanuskinaseinhibitorstherapyandmentalhealthoutcomeinrheumatoidarthritisasystematicreviewandmetaanalysis AT bagepallybhavanishankara associationbetweenjanuskinaseinhibitorstherapyandmentalhealthoutcomeinrheumatoidarthritisasystematicreviewandmetaanalysis |